A5014824285- Prostate Cancer Treatment and Research
- Estrogen and related hormone effects
- Cancer, Lipids, and Metabolism
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- Pancreatic and Hepatic Oncology Research
- Renal and related cancers
- Patient Dignity and Privacy
- Palliative Care and End-of-Life Issues
- Bladder and Urothelial Cancer Treatments
- Inflammatory Biomarkers in Disease Prognosis
- Cancer, Hypoxia, and Metabolism
- Ferroptosis and cancer prognosis
- Epigenetics and DNA Methylation
- Venous Thromboembolism Diagnosis and Management
- Chromatin Remodeling and Cancer
- Fibroblast Growth Factor Research
- Childhood Cancer Survivors' Quality of Life
- Radiomics and Machine Learning in Medical Imaging
- Mass Spectrometry Techniques and Applications
- Central Venous Catheters and Hemodialysis
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Diagnosis and Treatment
- Cardiac tumors and thrombi
- Hormonal and reproductive studies
NYU Langone Health
2025
NYU Langone’s Laura and Isaac Perlmutter Cancer Center
2025
The University of Texas MD Anderson Cancer Center
2022-2024
New York Hospital Queens
2019-2021
NewYork–Presbyterian Hospital
2019-2021
Cornell University
2019-2021
Presbyterian Hospital
2019-2021
Memorial Sloan Kettering Cancer Center
2019-2021
Weill Cornell Medicine
2020
Rutgers, The State University of New Jersey
2017
Abstract Purpose: Renal medullary carcinoma (RMC) is a highly aggressive malignancy defined by the loss of SMARCB1 tumor suppressor. It mainly affects young individuals African descent with sickle cell trait, and it resistant to conventional therapies used for other renal carcinomas. This study aimed identify potential biomarkers early detection disease monitoring RMC. Experimental Design: Integrated profiling primary untreated RMC tissues paired adjacent kidney controls was performed using...
<div>AbstractPurpose:<p>Renal medullary carcinoma (RMC) is a highly aggressive malignancy defined by the loss of SMARCB1 tumor suppressor. It mainly affects young individuals African descent with sickle cell trait, and it resistant to conventional therapies used for other renal carcinomas. This study aimed identify potential biomarkers early detection disease monitoring RMC.</p>Experimental Design:<p>Integrated profiling primary untreated RMC tissues paired adjacent...
<p>This pdf file contains Supplementary Figures S1-S5 and their legends.</p>
<p>The supplementary methods file contains additional details on the chromatin extraction and immuno-precipitation sequencing approaches.</p>
Abstract Purpose: To determine the efficacy and safety of risk-adapted combinations androgen signaling inhibitors inform disease classifiers for metastatic castration–resistant prostate cancers. Patients Methods: In a modular, randomized phase II trial, 192 men were treated with 8 weeks abiraterone acetate, prednisone, apalutamide (AAPA; module 1) then allocated to modules 2 or 3 based on satisfactory (≥50% PSA decline from baseline &lt;5 circulating tumor cell/7.5 mL) versus...
Background The Memorial Sloan Kettering Prognostic Score (MPS), a composite of the neutrophil‐lymphocyte ratio (NLR) and albumin, is an objective prognostic tool created as more readily available alternative to Glasgow Score. A prior analysis patients with metastatic pancreatic adenocarcinoma (mPDAC) suggested that MPS may predict survival, although it did not control for clinically relevant factors. Methods scores were calculated mPDAC treated at Cancer Center from January 1, 2011, December...
122 Background: Prostate cancer is often a disease of the frail in which androgen withdrawal can further risk morbidity and mortality. This study aimed to describe single institution experience with peripheral blockade using bicalutamide dutasteride (B+D) men hormone-sensitive prostate (HSPC) context body composition frailty. Methods: Patients HSPC treated B+D at MD Anderson Cancer Center between 2010 2022 were retrospectively identified. Baseline post-B+D frailty scores calculated G8...
<p>Supplementary Figure S8. Heatmap showing immune-related Level 1 Reactome and selected Cancer Hallmark pathways in bulk RNA sequencing of baseline metastatic lymph node biopsies from patients allocated to the Satisfactory (n=27) Unsatisfactory (n=13) groups.</p>
<div>AbstractPurpose:<p>To determine the efficacy and safety of risk-adapted combinations androgen signaling inhibitors inform disease classifiers for metastatic castration–resistant prostate cancers.</p>Patients Methods:<p>In a modular, randomized phase II trial, 192 men were treated with 8 weeks abiraterone acetate, prednisone, apalutamide (AAPA; <i>module 1</i>) then allocated to <i>modules 2</i> or <i>3</i> based on...
<p>Supplementary Figure S8. Heatmap showing immune-related Level 1 Reactome and selected Cancer Hallmark pathways in bulk RNA sequencing of baseline metastatic lymph node biopsies from patients allocated to the Satisfactory (n=27) Unsatisfactory (n=13) groups.</p>
<p>Supplementary Figure S2. Failure-free survival in Modules 2 and 3.</p>
<p>Criteria and Definitions: Trial eligibility criteria, dose reductions, failure-free survival</p>
<p>Supplementary Figure S10. Frequencies of copy number alterations.</p>
<p>Supplementary Figure S3. Immune cell populations in baseline metastatic biopsies within Satisfactory and Unsatisfactory groups.</p>
<p>Supplementary Figure S4. Immune cell densities by IHC across organ sites.</p>
<p>Criteria and Definitions: Trial eligibility criteria, dose reductions, failure-free survival</p>